Autosomal-dominant Stargardt-like macular dystrophy [Stargardt3 (STGD3)] results from single allelic mutations in the elongation of very-long-chain fatty acids-like 4 (ELOVL4), whereas recessive mutations lead to skin and brain dysfunction. ELOVL4 protein localizes to the endoplasmic reticulum, where it mediates the condensation reaction catalyzing the formation of very-long-chain (VLC) (C-28 to C-40) fatty acids, saturated and polyunsaturated (PUFA). The defective gene product is truncated at the C terminus, leading to mislocalization and aggregation in other organelles. We hypothesized that the STGD3 truncated mutant may generate mislocalized, and therefore toxic, keto intermediates of fatty acid elongation, thereby contributing to the disease process. Using cell-based and cell-free microsome assays, we found that the truncated protein lacked innate condensation activity. Coexpression of different forms of wild-type and mutant ELOVL4 revealed a large dominant-negative effect of mutant protein on ELOVL4 localization and enzymatic activity, resulting in reduced VLC-PUFA synthesis. The reduction in VLC-PUFA levels in STGD3 and age-related macular degeneration may be a contributing factor to their retinal pathology.
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Stargardt disease | condensing enzyme | photoreceptor degeneration T hree independent mutations in the last exon (exon 6) of the elongation of very-long-chain fatty acids-like 4 (ELOVL4) gene cause the pathogenesis of autosomal-dominant Stargardtlike juvenile macular dystrophy [Stargardt3 (STGD3)], resulting in loss of central vision with progressive degeneration of the macula and peripheral retina in humans (1) (2) (3) (4) . A recent study reported severe skin and brain dysfunction in patients with homozygous mutations in ELOVL4 (5). The resultant frameshift leads to premature termination of the encoded protein, loss of its C-terminal endoplasmic reticulum (ER) retention signal, and subsequent protein mislocalization and aggregation in cultured cells (4, (6) (7) (8) . In 2008, ELOVL4 was shown to be involved in the elongation of C26 to C28 very-long-chain (VLC) fatty acids, saturated (FA) and polyunsaturated (PUFA) (9) . VLC-PUFA (defined as containing 28-40 carbons) are components of retinal and brain phospholipids (10, 11) , and of testis and sperm sphingolipids (12) . In the retina, VLC-PUFA have been shown to be tightly associated with rhodopsin and suggested to aid in phototransduction (13) . VLC fatty acids are not normally found in the blood, so they accumulate in those tissues that express ELOVL4, such as, retina, skin, brain, and testes (14) .
ELOVL4 protein is targeted, via its C-terminal dilysine motif KXKXX, to ER membranes where fatty acid elongation occurs via a four-step cyclical process of condensation, reduction, dehydration, and reduction, yielding a fatty acid elongated by two carbons (15) . The initial condensation reaction and rate-limiting step is catalyzed by an elongase, mediated by iron-coordinating histidines in the active site, which condenses malonyl CoA, the two-carbon donor, and a fatty acyl-CoA to yield a 3-keto-acylCoA intermediate (16, 17) . The 3-keto compound is immediately reduced to the 3-hydroxy product, dehydrated to a trans-2,3-enoyl fatty acyl-CoA, which is further reduced to form the final product, a fatty acid two carbons longer than the precursor. The initial and final reduction steps are catalyzed by 3-keto-acyl-CoA reductase (KAR) trans-2,3-enoyl-CoA reductase (TER) enzymes, respectively (18) , both of which require NADPH as a cofactor. The dehydration step is carried out by one of four different 3-hydroxyacyl-CoA dehydratases (HACD1, HACD2, HACD3, and HACD4). The chain length of the final product, however, resides with the particular elongase that catalyzes the reaction and not with the reductase or dehydratase enzymes (19, 20) shown to be associated with ELOVL4 (21, 22) .
From our current knowledge of the localization and function of the ELOVL4 protein, we reasoned three possible explanations for the death of photoreceptor cells in dominant Stargardt disease: (i) VLC-PUFA play some vital role in the structure and/or function of photoreceptors that is compromised when the levels of VLC-PUFA are reduced, (ii) mislocalization of the truncated ELOVL4 protein causes cellular stress that leads to photoreceptor cell death, and (iii) mislocalization of an enzymatically active truncated ELOVL4 protein from the ER leads to accumulation of toxic products (i.e., 3-keto intermediates) in other organelles. The latter is a possibility because the truncated protein still contains the putative active site (1, 2) . Production and accumulation of these toxic keto intermediates by the truncated ELOVL4 could be an additive insult to the overall reduction in the VLC-PUFA products.
The toxic effects of ketones have been reported in several disease states. Ketones generated from the metabolism of hexane cause peripheral neuropathy and myopathy due to the formation of covalent bonds between 2,5-hexanedione and lysyl residues in myelin, resulting in loss of axonal transport (23, 24) . In patients with trifunctional protein (TFP) deficiencies, who lack the thiolase enzyme that breaks down the 3-keto-acyl-CoA intermediate to acyl-CoA and acetyl-CoA, the 3-keto acyl CoA intermediate can be reduced to the hydroxyacyl-CoA or spontaneously decarboxylated to the methylketone (25) . Under a ketogenic state, such as those induced by starvation or diabetes, ketones (acetoacetate) and ketone bodies generated from fat metabolism in the liver have been shown regulate the sympathetic nervous system by modulating the G-proteincoupled receptor 41 (GPR41) (26, 27) . Ketogenic acidosis has also been implicated in the increased occurrence of cardiac disorders (28, 29) . Thus, deciphering the contribution of the truncated mutant protein in generating keto intermediates is paramount and warrants an in-depth analysis.
Currently, little is known about the condensation activity of ELOVL4, which stems largely from the lack of commercially available VLC substrates. Here, using a gain-of-function methodology in cultured cells and in vitro microsome assay incubated with chemically synthesized VLC-PUFA-CoA substrate, we demonstrate that the STGD3 mutant protein is enzymatically inactive. Redirecting the STGD3 mutant protein to the ER by knocking in the C-terminal ER-retention signal did not rescue the functional deficit of the mutant protein. Moreover, we demonstrate that the elongation of VLC-PUFA by wild-type ELOVL4 is significantly impaired in the presence of the STGD3 mutant, an effect that is exacerbated when the STGD3 mutant is localized to the ER. In this report, we have addressed some of the key questions surrounding the STGD3 mutant and provide a better understanding of the enzymatic activity of ELOVL4 and its possible role in STGD3 pathogenesis.
Results
Expression of HA-Elovl4 Variants. Mutations in exon 6 of the ELOVL4 result in a truncated gene product (Fig. S1A, arrow) that causes autosomal-dominant Stargardt macular dystrophy (STGD3) in humans. To explore the function of STGD3 mutation (5-bp deletion) on VLC fatty acid elongation, we generated recombinant adenovirus carrying untagged and hemagglutinin (HA)-tagged full-length mouse Elovl4 cDNA (WT), the 5-bp STGD3 deletion (MUT) mutation (Fig. 1A) . To determine whether the function of the MUT is modulated by its cellular localization, we generated a STGD3 mutant fusion with the C-terminal ER retrieval signal of the WT (mERET) to direct the MUT to the ER (Fig. 1A) .
Western blotting of lysates from transduced HEK293T cells showed a double-banding pattern of HA immunoreactivity of WT at the predicted molecular weight of ∼34-36 kDa (Fig. 1B , Left). The MUT band was displaced down to ∼30-32 kDa, which was shifted up for mERET, corresponding to the addition of the retention signal. We confirmed that the double-banding pattern was due to the posttranslational modification of N-glycosylation, confirming previous reports (8) . Lysates from cells overexpressing the individual constructs and rat retinal extracts, when digested with peptide:N-glycosidase F (PNGase F), resulted in a single band at the predicted molecular weight of the ELOVL4 protein (Fig. 1B , Right) confirming N-glycosylation of overexpressed and endogenous ELOVL4 (Fig. S1B) .
We then determined the stability of expression of MUT and mERET compared with WT. Although steady-state levels of WT and MUT proteins showed comparable expression profiles ( Fig. S2A ), in the presence of cycloheximide (100 μg/mL) MUT showed rapid rate of degradation, levels of which dropped to 20% by 1 h compared with 50% of WT. mERET showed similar degradation kinetics as WT ( Fig. 1C and Fig. S2 B and D). Thus, MUT displays decreased stability, which was rescued by localization to the ER (mERET).
The subcellular localization of the ELOVL4 proteins generated from the constructs was determined after transient expression in HeLa cells and examination by immunofluorescence microscopy. HA immunoreactivity showed perinuclear staining of WT protein, which colocalized with the ER markers Calnexin and epoxide hydrolase-1 (EPHX1) (Fig. 1D and Fig. S3 , Top, respectively) (30) . MUT appeared mislocalized and punctate, and did not colocalize with Calnexin or EPHX1 ( Fig. 1D and Fig. S3 , Middle, respectively). These localization patterns are in agreement with previously published results from other groups (6) (7) (8) 31) . Addition of the ER retention signal to MUT (mERET) caused it to colocalize with Calnexin and EPHX1, displaying a phenotypic rescue ( Fig. 1D and Fig. S3 , Bottom, respectively).
The punctate and aggregated distribution of the MUT (Fig.  S4A , arrows) distinct from the reticular localization of ELOVL4, WT, and mERET was recapitulated in ARPE19 cells. In addition to altered subcellular localization, ARPE19 cells expressing MUT or mERET (72 h) displayed altered gross morphology compared with WT and GFP overexpression controls (Fig. S4B) . However, these alterations in cellular morphology did not result in ER stress (Fig. S4C) . Nevertheless, we cannot rule out alternate pathways of cellular stress as well as time-dependent amassing of ER stress factors. The morphological changes observed suggest modulations in cell adhesion factors, which remain to be explored.
STGD3 Mutant and VLC-PUFA Elongation. To explore the effect of mislocalization of the STGD3 mutant on VLC fatty acid elongation, we overexpressed HA-tagged Elovl4 variants (WT, MUT, and mERET) in HEK293T cells, which were supplemented with either 20:5n3 ( Fig. 2A and Fig. S5A ) or with an ELOVL4-specific VLC-PUFA precursor 34:5n3 ( Fig. 2B and Fig. S5B ). ELOVL4, both HA-tagged (WT) and untagged, elongated 20:5n3 to n3 VLC-PUFA with 34:5n3 being the predominant product ( Fig. 2A) and 34:5n3 to 36:5n3 VLC-PUFA. ELOVL4 and WT elongated the precursors to a similar extent, confirming that the HA-tag did not interfere with ELOVL4 activity. Analysis of the fatty acids revealed no detectable VLC-PUFA products in either MUT or mERET, similar to untransduced (UT) and GFP-expressing controls. PUFA products (<C28; Fig. S5A ) that were not dependent -treated samples showed a sharp decline in MUT expression to 20% compared with 50% of WT by 1 h. mERET degradation rate was comparable with WT (mean ± SD; n = 3; P < 0.05). (D) HeLa cells transiently transfected with HA-Elovl4 constructs were immunostained for HA (green) and Calnexin (red). WT showed homogenous perinuclear staining colocalizing with ER marker Calnexin, whereas MUT was distributed beyond the perinuclear regions and appeared to be punctate and aggregated. mERET showed a change from the MUT phenotype to a more WT subcellular localization pattern. (Scale bar, 10 μm.) on ELOVL4, including the immediate VLC-PUFA precursor 26:5n3 ( Fig. 2A) , were comparable in all experimental groups supplemented with 20:5n3, despite moderate fluctuations of the precursor taken up from the media. These results were recapitulated in ARPE19 cells overexpressing Elovl4 variants and supplemented with 20:5n3 ( Fig. S5 C and D) . This suggests that other components of the elongation machinery (KAR/TER reductase or HACD dehydratase enzymes) are not limiting due to MUT mislocalization. Thus, the elongation of VLC-PUFA by ELOVL4 is limited by the activity of the elongase generating its precursor ≤C26, levels of which are unaffected in all treated samples.
These results suggest that, when mislocalized, the MUT is enzymatically inactive, which may result from altered secondary structure or inability to interact with other components of the elongation machinery, or a combination of both. However, the cell-based assay does not discriminate between condensation and elongation aspects of fatty acid elongation and therefore does not discriminate between lack of innate condensation activity and deficiencies in interaction with KAR and TER reductases, which could affect VLC-PUFA synthesis.
Condensation Activity of STGD3 Mutant. To explore the condensation activity of ELOVL4, we used a cell-free microsome assay. Unlike purified elongase assays using proteoliposomes that allow for analysis of individual components (32, 33), using microsomes from cultured cells is especially useful to define MUT activity and any effect it may have on other endogenous elongases and components of the elongation machinery. The difficulty in applying the microsome assay to study the function of ELOVL4, is the lack of commercially available VLC fatty acyl-CoA substrates >C26 and solubility issues that arise from increased carbon chain lengths. We, therefore, chemically synthesized the CoA derivative of the VLC-PUFA 34:5n3 using the methodology of Hajra and Bishop (34) to explore ELOVL4 activity.
The ability of ELOVL4 variants and controls to incorporate [2- 14 C]malonyl-CoA was assessed in the presence or absence of reducing equivalents (NADPH/NADH) and 34:5n3-CoA. Omission of NADPH/NADH from the reaction allows formation of only the condensation 3-keto-acyl intermediate. Following methyl esterification, the reaction products were subjected to reversephase high-performance TLC, which separates the products based on size. During methanolysis, the 3-keto-acyl-CoA undergoes chemical decarboxylation to generate a 2-ketone, which migrates differently from the methyl ester of the elongated fatty acid, as described by Bernert and Sprecher (16) . WT and MUT microsomes showed comparable expression levels of the HAtagged proteins, whereas GFP served as an overexpression control (Fig. S6A ). In the in vitro microsome assay, WT generated the 3-keto condensation product from 34:5n3-CoA in the absence of NADPH/NADH (Fig. 3A , Top, open arrows), which is elongated to the VLC fatty acid product in the presence of NADPH/NADH (Fig. 3A , Top, closed arrows). ELOVL4-mediated condensation and subsequent elongation products increase with increasing concentrations of the 34:5n3-CoA ranging from 0.1 to 10 μM with maximal activity of 200 pmol at 5 μM of substrate ( Fig. 3 A and B) . MUT (Fig. 3A , Middle) and GFP (Fig. 3A , Bottom) microsomes also showed condensation (open arrows) and subsequent elongation activity (closed arrows) toward 34:5n3-CoA. However, when measured quantitatively, the incorporated radioactivity in the condensation products showed no difference between MUT and GFP, both of which were significantly lower than WT at all concentrations of substrate except 0.1 μM (Fig. 3B) .
The low levels of condensation and elongation products generated in HEK293T cells may result from endogenous expression of human ELOVL4 mRNA, which can be detected by quantitative real-time RT-PCR (Fig. S6B) . Because commercially available antibodies to the human protein are not reliable, we cannot detect the protein expression on Western blots. Endogenous human ELOVL4 mRNA is distinct from mouse Elovl4 mRNA, which shows a 50-fold overexpression in the same samples (Fig. S6C) . Alternatively, the low levels of condensation and elongation products generated in the microsome assay and undetectable in the cell-based assay could result from the overlapping activities of other ELOVLs with comparable active site motifs.
To compare the condensation activity of another ELOVL, endogenous ELOVL2, microsomes from cells expressing WT, MUT, and GFP were incubated with 5 μM 20:5n3-CoA. Condensation (open arrows) and elongation (closed arrows) activities were the same in the three different microsomal preparations (Fig. 3A , lanes "20:5n3 CoA," and Fig. 3C ), demonstrating that the membranes contained comparable levels of all of the enzymes necessary for fatty acid elongation. These results confirm that the MUT does not have innate condensation activity.
Furthermore, directing the mutant to the ER (mERET) did not rescue its condensation activity (Fig. S7) . mERET, despite comparable levels of protein expression to WT (Fig. S7A) , showed the same activity toward the 34:5n3-CoA as UT controls (lanes "34:5n3 CoA"; open and closed arrows), whereas endogenous activity with (lanes "20:5n3 CoA"; open and closed arrows) or without (lanes "No Acyl CoA"; brackets) substrate was comparable across samples (Fig. S7B) . MUT and mERET showed no specific elongation of the precursor and were comparable with untransduced (UT) and GFP-expressing controls. Levels of 26:5n3 were comparable across samples. (B) HEK293T cells show elongation of 34:5n3 to 36:5n3 (normalized to 22:0) with overexpression of ELOVL4 and WT but not with MUT and mERET, relative to controls (GFP and UT). Results are the mean ± SD (n = 3). Significance was assessed in comparison with GFP control (**P < 0.01). NT, nontreated.
STGD3 Mutant Has a Dominant-Negative Effect on ELOVL4 Localization
and Activity. Several groups have shown interaction between wildtype and mutant protein (8, 31, 35) , suggestive of a possible dominant-negative effect in disease manifestation. To determine the influence of this interaction on the enzymatic activity of ELOVL4, we coexpressed untagged ELOVL4 with each of the HA-tagged constructs (WT, MUT, and mERET) in ARPE19 cells. Immunocytochemistry revealed colocalization of ELOVL4 and WT, confirming again that the HA-tag had no effect on cellular distribution of the protein (Fig. 4A, Top) . In contrast, coexpression of ELOVL4 and MUT led to a punctate and aggregated phenotype of ELOVL4, indicating that the mutant protein was capable of altering the localization of WT protein (Fig. 4A, Middle) . This phenotype reverted to a more WT-like localization when coexpressed with mERET, which contains the ER retention signal (Fig. 4A, Bottom) .
To decipher the effect of this altered localization on the enzymatic activity of ELOVL4, we coexpressed untagged ELOVL4 in combination with GFP or HA-tagged WT, MUT, or mERET in ARPE19 cells and supplemented with 20:5n3 ( Fig. 4B and Fig. S8 A  and B) . GFP served as a coexpression control as it does not participate in VLC-PUFA elongation (Fig. 2) . The expression pattern of ELOVL4 was comparable across samples (with the exception of mERET+, which showed low levels of ELOVL4 expression) with variations in expression of HA-tagged mutants (Fig. S8A) . VLC-PUFA elongation by ELOVL4 was significantly reduced in the presence of MUT and more so with mERET. Moreover, when coexpressed with WT, ELOVL4 activity was further enhanced, suggesting that substrate was not limiting. This suggests that inhibition of ELOVL4 activity results from a physical interaction between ELOVL4 and the truncated proteins (MUT and mERET). Because fatty acid elongation products (<C28) not catalyzed by ELOVL4 were comparable in all experimental groups (Fig. S8B) , MUT-mediated inhibition of VLC-PUFA elongation is ELOVL4 specific and not a pan-elongase effect. These results are consistent with a dominant-negative effect of STGD3 mutant on ELOVL4 enzymatic activity. This dominant-negative effect was recapitulated in HEK293T cells coexpressing HA-tagged WT in combination with GFP, MUT, or mERET and supplemented with 20:5n3 (Fig. S8 C-E) . Elongation of VLC-PUFA by WT was significantly reduced in the presence of the MUT and more so with mERET.
We further assessed the effect of MUT on WT activity using the microsome assay and ELOVL4-specific substrate 34:5n3-CoA at 5 μM. Microsomes isolated from HEK293T cells expressing WT ELOVL4, individually or coexpressed in combination with MUT or mERET (Fig. S9A) , showed comparable levels of WT protein (Fig. S9B) , whereas MUT and mERET represented ∼39% and 57% of the total HA immunoreactivity in the coexpressed samples, respectively. GFP, MUT, and mERET served as individual overexpression controls. WT condensation activity was significantly reduced when coexpressed with MUT protein (Fig. 4C and Fig. S9C ) and was even further reduced when coexpressed with mERET, which directed the mutant back to the ER. Individually, GFP, MUT, and mERET showed no specific condensation activity toward the 34:5n3-CoA (Fig. S9C) . Thus, WT activity is modulated in the presence of truncated ELOVL4 (MUT or mERET), either by direct interaction with WT (suggested by altered localization of WT shown above) or through alterations in the availability of some component of the elongase machinery to ELOVL4.
The microsome data support our findings from the cell-based assay that the truncated protein has a dominant-negative effect on ELOVL4-mediated condensation activity.
Discussion
Humans with single-allelic mutations in ELOVL4 develop STGD3 macular dystrophy, which is characterized by early-onset vision loss with progressive degeneration of the macula and the peripheral retina (1-3). More recently, human patients with recessive mutations in the ELOVL4 have been reported to display severe skin (ichthyosis) and brain (intellectual disability and spastic quadriplegia) dysfunction (5). The skin defect is recapitulated in homozygous Elovl4 knock-in and KO mouse models that fail to generate ω-O-acylceramides containing VLC-FA species essential for the maintenance of skin barrier integrity (36) (37) (38) (39) . The recessive mutation as well as global KO in mice are neonatal lethal (36) (37) (38) (39) . Both dominant and recessive mutations in ELOVL4 suggest an important role for the VLC fatty acid products (≥C28) synthesized by ELOVL4, but do not preclude a possible effect of mutant protein in disease manifestation.
Mammalian ELOVL enzymes (ELOVL1-7) catalyze distinct elongation steps, mediating the first and rate-limiting condensation reaction catalyzed by iron-coordinating histidines during fatty acid elongation (40) (41) (42) (43) , a process that occurs in the ER. Since mutations in ELOVL4 occur downstream of the active site histidines, the possibility remains that the truncated gene product may be enzymatically active, generating keto intermediates of fatty acid elongation in cellular compartments where it may be toxic. Although the hydroxyl and the enoyl acyl-CoA intermediates are amenable to derivatization and detection by HPLC, detection of the keto intermediate is problematic due to the lack of an available hydroxyl or carboxylic group for derivatization and organic acid analysis (44) . The only methylketone ever detected is a 2-butanone resulting from β-ketothiolase enzyme deficiency (45) .
Analysis of the STGD3 mutant protein (MUT) in animal models has been limited largely due to the lack of an antibody that would detect mutant protein. The current study as well as others (7, 31, 35) have shown that tagged-MUT is mislocalized in cultured cells. Mislocalization of the tagged-MUT to photoreceptor outer segments and inner retinal layers in transgenic pigs results in aberrations in photoreceptor structure and function (46) . However, the effect of MUT on VLC-PUFA synthesis is undefined. This study reveals a functional consequence on ELOVL4 enzyme activity due to the mislocalization phenotype presented by the MUT protein. Specifically, we demonstrated that the MUT is inept in mediating the condensation reaction during the elongation of VLC fatty acids and therefore rules out the possibility of 3-keto intermediates generated from the enzymatic activity of the MUT as a causative agent for the disease phenotype. One of our most important finding is that the STGD3 mutant, although lacking innate condensation activity (Fig. 3) , exerted a dominant-negative effect specific to ELOVL4 enzymatic activity and the elongation of VLC fatty acids (Fig. 4) . The dominant-negative effect persisted even when the mutant protein was redirected to the ER, which significantly reduced VLC-PUFA elongation.
Our data suggest that mislocalization of the truncated product might actually be a protective mechanism in an attempt to preserve the activity of ELOVL4. This is supported by the finding that redirecting the mutant to the ER exacerbated the dominantnegative phenotype of the MUT, and as such is not a viable therapeutic option. Lack of activity, in addition to the decreased stability of the mutant protein, may indirectly affect the stability of ELOVL4 by association and thus lead to further reduction in VLC-PUFA. Thus, reduction of VLC-PUFA beyond critical levels may be a contributing factor to the associated photoreceptor, skin, and brain pathology observed in patients with mutations in ELOVL4.
Decline in VLC-PUFA levels have also been associated with age in control human donor eyes as well as in patients with agerelated macular degeneration (47) , suggesting an involvement of enzymes mediating fatty acid metabolism or insufficient dietary intake of VLC-PUFA precursors. Although ELOVL4 mutations/ variants have not been directly linked to the onset or progression of these age-related disorders, dietary or genetic interventions to elevate levels of VLC-PUFA in the retina may provide an avenue for therapy in alleviating or retarding maculopathies and retinal disorders that result from reduced VLC-PUFA levels. In conjunction with dietary supplementation, STGD3 patients may benefit further from ribozyme or RNAi-mediated knockdown of the defective gene product to possibly rescue dominant-negative effects and alterations in photoreceptor structure and function.
Materials and Methods
Adenovirus of Mouse Elovl4 Constructs. Mouse Elovl4 (wild type, 5-bp deletion, and mERET) were PCR-amplified and cloned in frame with a triple HA tag in MUT and mERET, which is further decreased with increased expression levels of the truncated protein (indicated by "+"). Levels of 26:5n3 were comparable across samples. Statistical significance was assessed in comparison with "ELOVL4+GFP" (*P < 0.05, **P < 0.01). (C ) Microsome elongase assay showed significant inhibition of WT condensation activity to 34:5n3-CoA by MUT (*P < 0.05) and mERET (***P < 0.001), whereas MUT and mERET alone showed no specific activity beyond background (GFP). Results are the mean ± SD (n = 3), and significance was assessed in comparison with WT.
without PNGase F (New England Biolabs) as described by Grayson and Molday (8) . Further details on Western blotting, antibodies, cycloheximide assay, and immunocytochemistry are available in SI Materials and Methods.
Fatty Acid Treatment and Analysis. ARPE19 cells (2 × 10 6 ) and HEK293T (4 × 10 6 ) cells were plated in 10-cm 2 tissue culture plates and transduced after 48 h with mouse Elovl4 adenovirus overnight. Cell were treated with 30 μg/mL fatty acid precursor conjugated with BSA and subsequently processed for lipid analysis as described by Agbaga et al. (9) . Lipids were extracted from cells according to the procedure described by Bligh and Dyer (48) . Fatty acid methyl esters (FAMES) were generated, extracted, and analyzed by GC-MS as described by Agbaga et al. (9) . Fatty acid molar values and relative mole percents were directly measured by GC-flame ionization detector using 15:0, 17:0, and 30:3n6 internal standards as described by Yu et al. (49) .
Elongase Assay. Elongase assay was performed as per Paul et al. (19) with some modifications. Microsomes were incubated in the presence or absence of NADPH/NADH with fatty acyl-CoA acceptor (either 20:5n3-CoA or 34:5n3-CoA) and 10 μM [2-
14 C]malonyl-CoA. FAMES were separated by reverse-phase TLC and analyzed by autoradiography and scintillation spectrometry. Further details on assay conditions, quantitation of radioactivity, microsome preparations, and synthesis of acyl-CoA are available in SI Materials and Methods.
Statistical Analysis. Statistical differences between experimental groups were analyzed using a multivariate ANOVA followed by post hoc Scheffé test using Statistica 2000 software (StatSoft) and Student t test. Data are represented as the mean ± SD. Significance is indicated by P value measurements with a P < 0.05 considered significant; *P < 0.05; **P < 0.01; ***P < 0.001.
